Invenio Therapeutics, Inc.

Cleveland, OH 44106

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $2.04MM
First Award Date 04/01/08
Most Recent Award Date 04/13/15

Key Personnel

Last Name Name Awards Contact
Agarwal Mukesh Kumar Agarwal 7
WALD DAVID WALD 1

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 04/13/15 - 03/31/16

DESCRIPTION (provided by applicant): Despite advances in cancer therapy, the majority of cancer therapeutics in use still exhibit significant toxicity and induce DNA damage. The DNA damage, though toxic to non-malignant cells, often plays an important role in killing cancer cells through the induction of p53. Recently, in order to develop less t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/01/14 - 05/31/15

DESCRIPTION (provided by applicant): Though AML is one of the most common forms of leukemia in adults;the 5 year survival is less than 20-50% in adults and significantly lowers in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia (APL), with all trans- retinoic acid (ATRA) illustr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): Though AML is one of the most common forms of leukemia in adults;the 5 year survival is less than 20-50% in adults and significantly lowers in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia (APL), with all trans- retinoic acid (ATRA) illustr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/26/11 - 08/31/12

DESCRIPTION (provided by applicant): Though AML is one of the most common forms of leukemia in adults;the 5 year survival is less than 20-50% in adults and significantly lowers in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia (APL), with all trans- retinoic acid (ATRA) illustr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 06/01/09 - 10/31/09

DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adults and significantly lower in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 04/08/08 - 09/30/09

DESCRIPTION (provided by applicant): Plant-derived compounds, particularly alkaloids, have historically been a successful source of currently used therapeutics. Recently, a plant-derived alkaloid was identified that is a potent acute myeloid leukemia (AML) differentiation-inducing compound. Differentiation therapy for AML holds significant promi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 04/01/08 - 09/30/09

DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults and despite advances in treatment the 5 year survival is less than 20-50% in adults and significantly lower in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia,...